Eyestem Research has announced the submission of IND application to CDSCO to start first in-human trials of Eyecyte-RPE™for subjects.

Eyestem has appointed Ravi Achar as Head- North America Strategy and also engaged Stradling Yocca Carlson & Rauth as its US law firm.

Existing investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at $46.4 million (INR 371 Cror...